Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

You may be eligible if

• Histologically confirmed ovarian epithelial or primary peritoneal carcinoma
• * Recurrent or persistent after initial standard surgery or chemotherapy
• * Incurable with standard surgery, chemotherapy, or radiotherapy
• At least 1 unidimensionally measurable target lesion
• * At least 20 mm by conventional techniques
• * At least 10 mm by spiral CT scan
• * Outside the area of prior radiotherapy
• Accessible to guided core needle biopsy
• Received 1 prior platinum-based chemotherapy regimen (e.g., carboplatin, cisplatin, or another organoplatinum compound) for primary disease
• * May have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment
• * Patients with only 1 prior platinum-based chemotherapy regimen must have an initial treatment-free interval of less than 12 months
• * Patients with an initial treatment-free interval of more than 12 months must have progressive disease after prior platinum-based chemotherapy regimen as second-line therapy
• No tumors involving major blood vessels
• No evidence of CNS disease (primary brain tumor or brain metastases) within the past 5 years
• Ineligible for higher priority Gynecologic Oncology Group (GOG) protocols (i.e., active phase III GOG protocols for the same patient population)
• Performance status - GOG 0-2 (patients who have received 1 prior regimen)
• Performance status - GOG 0-1 (patients who have received 2 prior regimens)
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• No known bleeding disorder or coagulopathy
• No active bleeding
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• serum glutamate oxaloacetate transaminase (SGOT) ≤ 2.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• PT (INR) ≤ 1.5 (INR 2-3 if on stable dose of therapeutic warfarin or low molecular weight heparin)
• Partial thromboplastin time (PTT) \< 1.2 times control
• Creatinine ≤ 1.5 times ULN
• Creatinine clearance \> 60 mL/min
• No proteinuria, as indicated by 1 of the following:
• * Negative urine dipstick
• * Urine protein \< 30 mg/dL
• * Urine protein \< 1,000 mg on 24-hour urine collection
• No clinically significant cardiovascular disease, including any of the following:
• * Uncontrolled hypertension
• * Myocardial infarction within the past 6 months
• * Unstable angina within the past 6 months
• * New York Heart Association class II-IV congestive heart failure
• * Serious cardiac arrhythmia requiring medication
• * Peripheral vascular disease ≥ grade 2
• No stroke within the past 5 years
• No pathologic condition that carries a high risk of bleeding
• No significant traumatic injury within the past 28 days
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• No uncontrolled seizures within the past 5 years
• No neuropathy (motor and sensory) ≥ grade 2
• No serious non-healing wound, ulcer, or bone fracture
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
• No active infection requiring parenteral antibiotics
• No known claustrophobia that would preclude MRI tolerance
• No ferromagnetic implants or pacers
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 3 months after study treatment
• At least 3 weeks since prior immunologic therapy directed at malignancy
• No prior bevacizumab
• No other concurrent immunotherapy directed at malignancy
• One additional prior cytotoxic regimen for recurrent or persistent disease allowed
• No prior non-cytotoxic chemotherapy for recurrent or persistent disease
• No concurrent chemotherapy directed at malignancy
• At least 1 week since prior hormonal therapy directed at malignancy
• No concurrent hormonal therapy directed at malignancy
• Concurrent hormone replacement therapy allowed
• Recovered from prior radiotherapy
• No concurrent radiotherapy directed at malignancy
• At least 28 days since prior major surgery or open biopsy and recovered
• At least 7 days since prior core biopsy or placement of vascular access device
• No anticipated need for major surgical procedure during study participation
• At least 3 weeks since other prior therapy directed at malignancy
• No prior anticancer therapy that would preclude study entry